A Phase 1 interventional study of TRK-250 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Toray Industries, Inc. Completed at 11 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Toray Industries, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 125th largest by enrollment of the 188 interventional ones that give a count, is one of 15 that started in 2018, is one of 39 in phase 1, and was the 131st registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Oorja Bio, Inc. · Sites in United States
Ages 40+
University of California, San Francisco · Sites in United States
Ages 18+
Trevi Therapeutics · Sites in United States
Ages 40+
Joseph C. Wu · Sites in United States
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United States, North Macedonia, Korea, Republic of and 1 more country
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 89 · Phase 3 39 · Phase 4 6
First in 1999; this study’s year is marked. 15 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 61 across the 188 interventional studies, 320 across the 45 observational. Of the 170 that completed or were terminated, 86 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 236 have an industry lead sponsor. The 10 most frequent:
Toray Industries, Inc is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Toray Industries, Inc has 1 study filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Idiopathic Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT07868419Phase 3Trevi TherapeuticsIdiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | 2027-08 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT06853145University of VirginiaHyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis | 2026-12 |
| NCT03478553University of Colorado, DenverThe Genetics of Pulmonary Fibrosis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TRK-250
Drug: Placebo
single and multiple doses (4 weeks)
single and multiple doses (4 weeks)
Incidence and Severity of Adverse Events
Number of patients reporting Adverse Events Number of patients by severity reporting Adverse Events
Time frame: Up to 14 days after last dose
A total of 34 subjects were randomized to treatment, with 16 subjects in Part A and 18 subjects in Part B.
| Milestone | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 6 |
| Completed | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Number of patients reporting Adverse Events Number of patients by severity reporting Adverse Events
| Participants | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Subjects with AEs | 1 | 0 | 3 | 2 | 1 | 3 | 2 | 3 | 3 |
| Mild(Severity) | 0 | 0 | 2 | 1 | 1 | 2 | 1 | 0 | 3 |
| Moderate(Severity) | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 2 | 0 |
| Severe(Severity) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Collected over Up to 14 days after last dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PartA:TRK-250 2mg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| PartA:TRK-250 10mg | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| PartA:TRK-250 30mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| PartA:TRK-250 60mg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| PartA:Pooled Placebo | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| PartB:TRK-250 10mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| PartB:TRK-250 30mg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| PartB:TRK-250 60mg | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| PartB:Pooled Placebo | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Event | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/4 | 0/6 |
| Event | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo |
|---|---|---|---|---|---|---|---|---|---|
| ArrhythmiaCardiac disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Anal fissureGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Alanine aminotransferase increasedInvestigations | 0/3 | 0/3 | 1/3 | 1/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Eosinophil count increasedInvestigations | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Heart rate irregularInvestigations | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/3 | 1/3 | 0/4 | 1/4 | 0/4 | 0/4 | 1/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/3 | 1/3 | 0/4 | 0/4 | 0/4 | 1/4 | 0/6 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 1/4 | 0/4 | 0/4 | 0/4 | 0/6 |
| Age, Customized(years) | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 74 (70 to 76) | 70 (66 to 73) | 76 (70 to 80) | 69 (66 to 74) | 75 (67 to 79) | 64 (48 to 74) | 70 (59 to 75) | 74 (66 to 78) | 75 (70 to 77) | 72 (48 to 80) |
| Sex: Female, Male(Participants) | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 7 |
| Male | 1 | 2 | 2 | 2 | 4 | 4 | 4 | 2 | 6 | 27 |
| Race/Ethnicity, Customized(Participants) | PartA:TRK-250 2mg | PartA:TRK-250 10mg | PartA:TRK-250 30mg | PartA:TRK-250 60mg | PartA:Pooled Placebo | PartB:TRK-250 10mg | PartB:TRK-250 30mg | PartB:TRK-250 60mg | PartB:Pooled Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Race — White | 3 | 3 | 2 | 3 | 4 | 4 | 4 | 4 | 6 | 33 |
| Race — Black or African Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Apr 2022, 40 months.
Results were first posted in Oct 2023, 1 year 6 months after primary completion.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 40 months is above that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →
Toray Industries, Inc